Nkarta Reports Q3 2025 Financial Results and Clinical Highlights for NKX019 Trial in Autoimmune Diseases

Nkarta has reported its Q3 2025 financial results, highlighting the enrollment of the second dose-escalation cohort for its NKX019 clinical program. The company has observed deep B-cell depletion in patients treated with fludarabine and cyclophosphamide, compared to partial B-cell depletion in those receiving cyclophosphamide alone. Nkarta's cash balance stands at $316.5 million, expected to fund operations into 2029. Initial data for NKX019 in multiple autoimmune indications is expected to be presented at a medical conference in 2026.